NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus (BDBV) and other Ebola viruses in the Democratic Republic of Congo. The trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026.
Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. The company said NV-387 is designed to attack the virus and reduce viral load and is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort.
If successful, the oral treatment could be readily deployed in resource-limited settings, where traditional injectable Ebola therapies may be difficult to administer. NanoViricides characterized NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses and said there is a rationale for potential activity against Bundibugyo and other Ebola viruses. For full details, see the company’s press release.
The news matters because the ongoing Bundibugyo outbreak in the DRC highlights the need for easy-to-use therapeutics that can be deployed rapidly in remote areas. An oral gummy that does not require refrigeration or trained personnel for administration could significantly improve outbreak response. NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide™ class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc.
Beyond Ebola, NV-387 is being developed as a broad-spectrum antiviral for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company’s other advanced candidate is NV-HHV-1 for Shingles. NanoViricides holds a worldwide exclusive perpetual license to TheraCour’s nanomedicine technology for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, and Ebola/Marburg viruses.
The company’s progress with NV-387 could position it as a key player in pandemic preparedness and response. However, as is customary in drug development, the path to approval is lengthy and requires substantial capital, and there can be no assurance that any candidate will show sufficient effectiveness and safety for human clinical development. The latest updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
This announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and other services. The platform ensures that news like this reaches a wide audience of investors, journalists, and the public.
